Spiro Medical, which debuted last year, reeled in $67 million in series A funding it plans to use to develop its novel ...
Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe asthma that has been billed as a major new product for the drugmaker. In the ...
Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is GSK's depemokimab, a long-acting anti-IL-5 antibody for severe asthma and an ...
Bored Panda on MSN
Lingering knowledge: 93 intriguing facts that are hard to forget
The world feels ordinary until a single detail shifts your perspective. A quiet fact can linger in your thoughts, reshaping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback